Article citationsMore>>
Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L., Hallin, M.E., Wickman, G.R., Amundson, K., Chen, J.H., Rewolinski, D.A., Yamazaki, S., Wu, E.Y., McTigue, M.A., Murray, B.W., Kania, R.S., O’Connor, P., Shalinsky, D.R. and Bender, S.L. (2008) Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research, 14, 7272-7283.
http://dx.doi.org/10.1158/1078-0432.CCR-08-0652
has been cited by the following article:
-
TITLE:
Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma
AUTHORS:
Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Takayuki Ohzeki, Yosuke Sato, Junryo Rii, Hirotsugu Uemura, Tomohiko Ichikawa, Takeshi Ueda
KEYWORDS:
Axitinib, Renal Cell Carcinoma, First Line
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.8,
July
28,
2015
ABSTRACT: Previous study
reported that patients treated with axitinib as second-line therapy had longer
median progression-free survival than those treated with sorafenib for
metastatic renal cell carcinoma (mRCC). In this study, we reviewed our
experience of axitinib as a first-line therapy for mRCC in Japanese patients,
focusing on its efficacy and safety. We retrospectively assessed 26 patients
treated with axitinib as a first-line therapy for mRCC from July 2010 to July
2014 at Chiba Cancer Center and Kinki University Hospital. Observation period
was 24.6 ± 18.3 months. The objective response rate was 50.0%, and the median
progression-free survival was 27.5 months. Overall survival was not estimable.
Common grade 3 adverse events were hypertension in 19 patients and proteinuria
in 5 patients. Axitinib demonstrated significant efficacy as a first-line therapy
in Japanese patients with mRCC. Careful monitoring and management of the
adverse effects may help to control its toxicities.
Related Articles:
-
Kengo Hirayama, Ya Su, Yasuyuki Ikezawa, Megumi Chiba, Kenichiro Ito, Michiko Yuki
-
Hoda Abdel Moety, Gihan I. Khalil, Rania M. El Sharkawy, Marwa K. El Ghandour, Fady S. Moiety, Hesham A. F. Salem
-
Jessica J. Sánchez García, Luis Ortiz-Frade, Elena Martínez-Klimova, Juan C. García Ramos, Marcos Flores-Alamo, Teresa Ramírez Apan, Elena I. Klimova
-
Vipa Boonkitticharoen, Boonchu Kulapaditharom, Noppadol Larbcharoensub, Phurich Praneetvatakul, Thongchai Bhongmakapat
-
Xinfeng Li, Xiaofu Li, Wenrui Zhou, Gaoxiong Wang, Wei Wang